Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  MedChemComm

• Publication date

  2017-08-16

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1039/c7md00213kPMID 30108871PMCID PMC6072211
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping.

  2017cited by this paper
• 2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors.

  2017cited by this paper
• Prolonged and tunable residence time using reversible covalent kinase inhibitors

  2015cited by this paper
• Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction.

  2015cited by this paper
• First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.

  2015cited by this paper
• Quantifying tetrahedral adduct formation and stabilization in the cysteine and the serine proteases

  2015cited by this paper
• Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies.

  2015cited by this paper
• Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.

  2014cited by this paper
• Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4.

  2014cited by this paper
• Molecular Mechanisms of Aldehyde Toxicity: A Chemical Perspective

  2014cited by this paper
• Structural analysis of the human fibroblast growth factor receptor 4 kinase.

  2014cited by this paper
• Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?

  2014cited by this paper
• Targeting the fibroblast growth factor receptors for the treatment of cancer.

  2013cited by this paper
• A novel class of highly potent irreversible hepatitis C virus NS5B polymerase inhibitors.

  2012cited by this paper
• AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.

  2012cited by this paper
• Targeted Covalent Enzyme Inhibitors

  2012cited by this paper
• Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.

  2011cited by this paper
• Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors.

  2011cited by this paper
• Direct STD NMR identification of beta-galactosidase inhibitors from a virtual dynamic hemithioacetal system.

  2010cited by this paper
• Intramolecular hydrogen bonding in medicinal chemistry.

  2010cited by this paper
• A structure-guided approach to creating covalent FGFR inhibitors.

  2010cited by this paper
• Global analysis of cellular protein translation by pulsed SILAC

  2009cited by this paper
• The conformational plasticity of protein kinases.

  2002cited by this paper
• A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice.

  2002cited by this paper
• Discovery and structure-activity studies of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors

  1997cited by this paper
• The Curtin-Hammett principle and the Winstein-Holness equation: new definition and recent extensions to classical concepts

  1986cited by this paper
• Recent progress in the medicinal chemistry of 2,4-diaminopyrimidines.

  1982cited by this paper

• Substitution-Induced Mechanistic Switching in SNAr-Warheads for Cysteine Proteases

  2024cites this paper
• Discovery of electrophilic degraders that exploit SNAr chemistry

  2024cites this paper
• Exploring 2-Sulfonylpyrimidine Warheads as Acrylamide Surrogates for Targeted Covalent Inhibition: A BTK Story

  2024cites this paper
• Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update.

  2024cites this paper
• Vinylpyridine as a Tunable Covalent Warhead Targeting C797 in EGFR.

  2024cites this paper
• Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on SNAr Electrophiles.

  2024cites this paper
• Azaindole derivatives as potential kinase inhibitors and their SARs elucidation.

  2023cites this paper
• Design, synthesis and biological evaluation of indazole derivatives as selective covalent inhibitors of FGFR4 in wild-type and gatekeeper mutants.

  2023cites this paper
• Insight into the design of FGFR4 selective inhibitors in cancer therapy: Prospects and challenges.

  2023cites this paper
• Discovery and Structural Optimization of Novel Quinolone Derivatives as Potent Irreversible Pan-Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors.

  2023cites this paper
• Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review

  2022cites this paper
• Discovery of Novel 7-Azaindole Derivatives as Selective Covalent Fibroblast Growth Factor Receptor 4 Inhibitors for the Treatment of Hepatocellular Carcinoma.

  2022cites this paper
• Design, Synthesis, and Biological Evaluation of 5-Formyl-pyrrolo[3,2-b]pyridine-3-carboxamides as New Selective, Potent, and Reversible-Covalent FGFR4 Inhibitors.

  2022cites this paper
• Discovery and Characterization of a Novel Series of Chloropyrimidines as Covalent Inhibitors of the Kinase MSK1

  2022cites this paper
• Design, Synthesis, and Biological Evaluation of 2-Formyl Tetrahydronaphthyridine Urea Derivatives as New Selective Covalently Reversible FGFR4 Inhibitors.

  2022cites this paper
• Advances in reversible covalent kinase inhibitors

  2021cites this paper
• Discovery of a Potent and Highly Isoform-Selective Inhibitor of the Neglected Ribosomal Protein S6 Kinase Beta 2 (S6K2)

  2021cites this paper
• Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors.

  2021cites this paper
• Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors.

  2021cites this paper
• N-(6-Chloro-3-nitropyridin-2-yl)-5-(1-methyl-1H-pyrazol-4-yl)isoquinolin-3-amine

  2021cites this paper
• Advances in covalent kinase inhibitors.

  2020cites this paper
• Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.

  2020cites this paper
• Covalent Kinase Inhibitors: An Overview

  2020cites this paper
• Curse or Cure? A Perspective on the Developability of Aldehydes as Active Pharmaceutical Ingredients.

  2020cites this paper
• FGFR4 complex with N-(3-chloro-2-((5-((2,6-dichloro-3,5-dimethoxybenzyl)oxy)pyrimidin-2-yl)amino)-5-fluorophenyl)acrylamide

  2019cites this paper
• Novel 7-formyl-naphthyridyl-ureas derivatives as potential selective FGFR4 inhibitors: Design, synthesis, and biological activity studies.

  2019cites this paper
• Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors

  2019cites this paper
• Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4.

  2019cites this paper
• FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer

  2019cites this paper
• Fibroblast growth factor receptor inhibitors: patent review (2015–2019)

  2019cites this paper
• 2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4.

  2018cites this paper
• Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.

  2018cites this paper
• Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.

  2018cites this paper
• H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.

  2017cites this paper